Chemexpress(SH:688131) Zheng Quan Zhi Xing·2025-07-08 09:13Core Viewpoint - The announcement details the listing and circulation of restricted shares related to the acquisition of assets by Shanghai Haoyuan Pharmaceutical Co., Ltd, with a total of 4,493,210 shares set to be listed on July 16, 2025 [1][9]. Summary by Sections Listing of Restricted Shares - The company will list 4,493,210 restricted shares, which were issued to specific investors for asset acquisition and fundraising [1][2]. - The shares were registered on December 22, 2022, following approval from the China Securities Regulatory Commission [2]. Changes in Share Capital - Following the issuance of shares, the total share capital of the company increased from 104,078,810 shares to 106,982,272 shares [2]. - The company’s total share capital further increased to 150,217,339 shares after a capital increase of 0.40 shares per existing share was approved [3]. Performance Compensation - The shareholders involved in the asset acquisition, including WANG YUAN and others, are required to fulfill performance compensation obligations due to unmet performance commitments by the acquired company [6][8]. - A total of 47,725 shares were repurchased and canceled as part of the performance compensation process, reducing the total share capital to 211,561,848 shares [7]. Compliance and Verification - The independent financial advisor confirmed that the shareholders have adhered to their commitments regarding the lock-up period and performance compensation [8][9]. - The listing of the restricted shares complies with relevant regulations and the company’s disclosure is deemed accurate and complete [9]. Details of the Restricted Shares - The total number of restricted shares being listed represents 2.12% of the company's total share capital as of July 7, 2025 [10].